Chemoattraction of neoplastic glial cells with CXCL10, CCL2 and CCL11 as a paradigm for a promising therapeutic approach for primary brain tumors
| dc.contributor.author | Déry, Laurence | |
| dc.contributor.author | Charest, Gabriel | |
| dc.contributor.author | Guérin, Brigitte | |
| dc.contributor.author | Akbari, Mohsen | |
| dc.contributor.author | Fortin, David | |
| dc.date.accessioned | 2022-11-19T16:10:05Z | |
| dc.date.available | 2022-11-19T16:10:05Z | |
| dc.date.copyright | 2021 | en_US |
| dc.date.issued | 2021 | |
| dc.description.abstract | Chemoattraction is a normal and essential process, but it can also be involved in tumorigenesis. This phenomenon plays a key role in glioblastoma (GBM). The GBM tumor cells are extremely difficult to eradicate, due to their strong capacity to migrate into the brain parenchyma. Consequently, a complete resection of the tumor is rarely a possibility, and recurrence is inevitable. To overcome this problem, we proposed to exploit this behavior by using three chemoattractants: CXCL10, CCL2 and CCL11, released by a biodegradable hydrogel (GlioGel) to produce a migration of tumor cells toward a therapeutic trap. To investigate this hypothesis, the agarose drop assay was used to test the chemoattraction capacity of these three chemokines on murine F98 and human U87MG cell lines. We then studied the potency of this approach in vivo in the well-established syngeneic F98- Fischer glioma-bearing rat model using GlioGel containing different mixtures of the chemoattractants. In vitro assays resulted in an invasive cell rate 2-fold higher when chemokines were present in the environment. In vivo experiments demonstrated the capacity of these specific chemoattractants to strongly attract neoplastic glioblastoma cells. The use of this strong locomotion ability to our end is a promising avenue in the establishment of a new therapeutic approach in the treatment of primary brain tumors. | en_US |
| dc.description.reviewstatus | Reviewed | en_US |
| dc.description.scholarlevel | Faculty | en_US |
| dc.description.sponsorship | Funding was provided by several donations and scholarships from the following organizations: La rose des vents, Fondation du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Centre de recherche du CHUS (CRCHUS), Centre d’imagerie moléculaire de Sherbrooke (CIMS) and Centre d’excellence en Neurosciences de l’Université de Sherbrooke (CNS). | en_US |
| dc.identifier.citation | Déry, L., Charest, G., Guérin, B., Akbari, M., & Fortin, D. (2021). “Chemoattraction of neoplastic glial cells with CXCL10, CCL2 and CCL11 as a paradigm for a promising therapeutic approach for primary brain tumors.” International Journal of Molecular Sciences, 22(22), 12150. https://doi.org/10.3390/ijms222212150 | en_US |
| dc.identifier.uri | https://doi.org/10.3390/ijms222212150 | |
| dc.identifier.uri | http://hdl.handle.net/1828/14509 | |
| dc.language.iso | en | en_US |
| dc.publisher | International Journal of Molecular Sciences | en_US |
| dc.subject | neuro-oncology | |
| dc.subject | brain tumor | |
| dc.subject | glioblastoma | |
| dc.subject | chemokine | |
| dc.subject | migration | |
| dc.subject | Laboratory for Innovations in Micro Engineering (LiME) | |
| dc.subject.department | Department of Mechanical Engineering | |
| dc.title | Chemoattraction of neoplastic glial cells with CXCL10, CCL2 and CCL11 as a paradigm for a promising therapeutic approach for primary brain tumors | en_US |
| dc.type | Article | en_US |